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Objective: Compared with bone marrow-derived MSC, embryo-derived MSC
have greater expansion and differentiation potentials. T helper cell 17(Th17)
and interleukin 17(IL-17) is closely related to the occurrence and develop-
ment of Lupus. The glial cell-derived neurotrophic factor (GDNF) which is
closely related to the kidney development is found to be a kidney protection
factor and can increase the renal protective effects of stem cells as well.
Persephin (PSP) is a member of the family of GDNF and also involves in
the kidney development. We investigated the effects of human embryonic
MSC (hMSC) in lupus nephritis in MRL/lpr mice.
Methods: The MRL/lpr mice were divided into 2 groups: Control (nZ 16) and
hMSC (n Z 16) groups. hMSC were injected at one dose of 1 106/200 ul
twice (at the 16th and 19th weeks of age) through tail vein. Mice were sacri-
ficed at 24 weeks of age. Multi-treatment of hMSC was able to increase the
survival, decrease the levels of 24-hour proteinuria, and anti-double-
stranded DNA (dsDNA) antibody.
Results: hMSC treatment alleviated the extent of renal injury such as cres-
cent formation and interstitial inflammatory cell infiltration in MRL/lpr
mice. hMSC treatment also inhibited Th17 cell differentiation in spleen
and decrease the serum level of IL-17. The level of GDNF and PSP was
increased in renal of hMSC treatment MRL/lpr mice.Figure 1. hMSC transplantation alleviates lupus nephritis in MRL/lpr mice.
(A) hMSC treatment prolongs survival (p < 0.01 vs Control). (B) hMSC1561-5413significantly reduced urine protein (*p < 0.05 vs Control). (C) Representative
hematoxylin and eosin staining of renal sections from each group. Original
magnification, 400. (D, E) Western blot analyses showed that hMSC treat-
ment MRL/lpr mice has increased expression of GDNF and PSP (*p < 0.05
vs Control).
Conclusion: These findings indicate that hMSCs transplantation might be a
potentially promising approach in the treatment of lupus nephritis, possibly by
inhibiting Th17 cell differentiation and increasing GDNF and PSP level in renal.http://dx.doi.org/10.1016/j.hkjn.2015.08.128
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Objectives: Adrenomedullin (ADM), a vasodilating peptide comprising 52
amino acids, confers anti-inflammatory properties. Although our previous
study identified a negative association between serum ADM levels and pro-
teinuria in lupus nephritis patients, none has explored the in-vivo effect
of ADM in lupus nephritis. We evaluated the effects of ADM in nephritis,
splenic lymphocytes/macrophages and autoantibody profile in MRL/Faslpr
mice before and after lupus-like disease onset.
Methods: ADM (27 mcg/0.2 ml normal saline [NS]) or 0.2ml NS was adminis-
tered intraperitoneally into 6-week (pre-lupus) and 12-week old (adult
group) MRL/Faslpr mice thrice weekly for 18 and 6 weeks respectively.
Upon treatment completion, urine protein and red cell levels were semi-
quantified. Cervical and axillary lymph nodes (LN) were weighed. Splenic
B (B220+) and T lymphocytes (CD4+ and CD8+) and macrophages (CD11b+)
were enumerated by flow cytometry. Kidneys were studied by immunofluo-
rescence for C3, C1q, anti-dsDNA and immunoglobulins (Ig)A, IgM and IgG de-
positions. Serum anti-dsDNA, -Sm, -ribosomal-P and -SSA/B autoantibodies
were measured by immunoassays. The in-vitro effects of ADM on splenic B
and T cell activation, proliferation and apoptosis were assessed with and
without CpG and anti-CD3/CD28 stimulations for 72 hours.
Results: Proteinuria (p Z 0.007) and LN weight (p Z 0.003) were signifi-
cantly lower in the ADM-treated adult mice than their NS-treated counter-
parts. Lower LN weight (p Z 0.036) but not proteinuria, was noted in the
ADM-treated pre-lupus group than their NS-treated counterparts. Serum
autoantibody levels, and the splenic lymphocyte and macrophage numbers
did not differ between both ADM-treated groups and their respective NS-
treated counterparts. ADM-treated adult mice had significantly reduced
renal Ig and complement depositions than their NS-treated counterparts.
ADM treatment did not alter the activation, apoptosis and proliferation of
splenic lymphocytes in vitro.
Conclusion: Exogenous ADM treatment reduced LN weight, proteinuria
and renal Ig and complement depositions in adult MRL/Faslpr mice
